



SHANGHAI PHARMACEUTICALS HOLDING CO., LTD.*

上海醫藥集團股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(於中華人民共和國註冊成立的股份有限公司)

(Stock Code/股份代號: 2607)

NOTIFICATION LETTER 通知信函

29 April 2026

Dear Shareholder,

Shanghai Pharmaceuticals Holding Co., Ltd.* (the "Company")

Notice of Publication of Corporate Communications and Invitation to Provide Email Address

The English and Chinese versions of the Company's Annual Report are available on the Company's website at www.sphchina.com and the Hong Kong Exchanges and Clearing Limited at website at www.hkexnews.hk (the "HKEX website").

To ensure that you receive timely updates in the future, we invite you to provide your valid email address to us by completing the Provision of Email Address Form on the reverse side and return it to the Company's Hong Kong Share Registrar, Tricor Investor Services Limited ("Vistra"), at 17/F, Far East Finance Centre, 16 Harcourt Road, Hong Kong, or by email at 2607-ecom@vistra.com. You will receive electronic notifications on the availability of corporate communications on the Company's website in the future.

It is the responsibility of the shareholder to provide an email address that is functional. If the Company does not receive a functional email address from you, you will be unable to receive any notification regarding the publication of Corporate Communications. The Company will be considered to have complied with the Listing Rules if it sends Actionable Corporate Communications to the email address provided by you without receiving any "non-delivery message".

Should you have any queries relating to any of the above matters, please call Vistra's telephone hotline at (852) 2980 1333 during business hours from 9:00 a.m. to 6:00 p.m.(Hong Kong time), Monday to Friday, excluding public holidays, or send an email to 2607-ecom@vistra.com.

Yours faithfully,

Shanghai Pharmaceuticals Holding Co., Ltd.*

Note: Corporate Communications include but are not limited to (a) the directors' report, its annual accounts together with a copy of the auditors' report and, where applicable, its summary financial report; (b) the interim report and, where applicable, summary interim report; (c) a notice of meeting; (d) a listing document; (e) a circular; (f) a reply slip and (g) a proxy form. Actionable Corporate Communications refer to any corporate communications that seek instructions from the shareholders of the Company on how they wish to exercise their rights or make elections as the Company's shareholders.

** For identification purpose only*

各位股東：

上海醫藥集團股份有限公司（「本公司」）

公司通訊發佈通知及邀請提供電郵地址

本公司的年報的中、英文版本已上載於本公司網站 www.sphchina.com 及香港交易及結算所有限公司網站 www.hkexnews.hk（「香港交易所網站」）。

為確保閣下日後能及時收到更新資訊，我們邀請閣下提供閣下的有效電郵地址。請於背面的電郵地址提供表格填寫閣下的有效電郵地址，然後交回至本公司的香港股份過戶處卓佳證券登記有限公司（「卓佳」），地址為香港夏慤道16號遠東金融中心17樓，或電郵至 2607-ecom@vistra.com。閣下日後將會收到本公司的公司通訊已上載於本公司網站的電子通知。

股東有責任提供有效的電郵地址。如本公司沒有收到閣下的有效電郵地址，閣下將無法收到任何有關發佈公司通訊的通知。當本公司向閣下提供的電郵地址發送可供採取行動的公司通訊時而沒有收到任何「未送達」的訊息，公司將被視為已遵守上市規則。

如閣下對上述事項有任何疑問，請致電卓佳電話熱線(852)2980 1333，辦公時間為星期一至五（公眾假期除外）上午9時正至下午6時正（香港時間），或電郵至 2607-ecom@vistra.com。

上海醫藥集團股份有限公司

謹啓

2026年4月29日

附註：公司通訊文件包括但不限於：(a)董事會報告、年度財務報表連同核數師報告及如適用的財務摘要報告；(b)中期報告及如適用的中期摘要報告；(c)會議通告；(d)上市文件；(e)通函；(f)回條；及(g)委任代表表格。可供採取行動的公司通訊是指任何涉及要求本公司的股東指示其擬如何行使其有關股東權利的公司通訊。

* 僅供識別

